WO2022194096A1 - 雌激素受体调节剂 - Google Patents
雌激素受体调节剂 Download PDFInfo
- Publication number
- WO2022194096A1 WO2022194096A1 PCT/CN2022/080680 CN2022080680W WO2022194096A1 WO 2022194096 A1 WO2022194096 A1 WO 2022194096A1 CN 2022080680 W CN2022080680 W CN 2022080680W WO 2022194096 A1 WO2022194096 A1 WO 2022194096A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- alkyl
- methyl
- group
- alkylamino
- Prior art date
Links
- 229940102550 Estrogen receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 102000015694 estrogen receptors Human genes 0.000 claims abstract description 24
- 108010038795 estrogen receptors Proteins 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- -1 hydroxy, amino Chemical group 0.000 claims description 71
- 125000005843 halogen group Chemical group 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 26
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 20
- 125000006323 alkenyl amino group Chemical group 0.000 claims description 20
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 15
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 10
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000732 arylene group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims description 4
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000002346 iodo group Chemical group I* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 158
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 95
- 239000000243 solution Substances 0.000 description 84
- 238000003786 synthesis reaction Methods 0.000 description 65
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 63
- 230000015572 biosynthetic process Effects 0.000 description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 62
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- 239000007787 solid Substances 0.000 description 52
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 42
- 239000012043 crude product Substances 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 238000004440 column chromatography Methods 0.000 description 37
- 238000004809 thin layer chromatography Methods 0.000 description 37
- 229910052757 nitrogen Inorganic materials 0.000 description 33
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 13
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 13
- 229910000024 caesium carbonate Inorganic materials 0.000 description 13
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- MFIGJRRHGZYPDD-UHFFFAOYSA-N n,n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)NCCNC(C)C MFIGJRRHGZYPDD-UHFFFAOYSA-N 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 6
- URBUZQPPQLQHBZ-UHFFFAOYSA-N 1-fluoro-3-iodopropane Chemical compound FCCCI URBUZQPPQLQHBZ-UHFFFAOYSA-N 0.000 description 5
- HPRXZPGEMSDKFT-IANOAQMISA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1Br Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1Br HPRXZPGEMSDKFT-IANOAQMISA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WDHOIABIERMLGY-CMJOXMDJSA-N N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine Chemical compound FCCCN1CC(C1)NC=1C=NC(=CC=1)[C@H]1N([C@@H](CC2=C3C(=CC=C12)NN=C3)C)CC(F)(F)F WDHOIABIERMLGY-CMJOXMDJSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 5
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- DFBDRVGWBHBJNR-BBNFHIFMSA-N (e)-3-[3,5-difluoro-4-[(1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H](N2CC(C)(C)F)C)=C(F)C=C(\C=C\C(O)=O)C=C1F DFBDRVGWBHBJNR-BBNFHIFMSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- ZBBKACDNAJRELO-UHFFFAOYSA-N 7-bromo-3-trityl-1,3-benzoxazol-2-one Chemical compound Brc1cccc2n(c(=O)oc12)C(c1ccccc1)(c1ccccc1)c1ccccc1 ZBBKACDNAJRELO-UHFFFAOYSA-N 0.000 description 4
- 229940125815 AZD9833 Drugs 0.000 description 4
- QBLSBTDQYOUKCK-NHOCJEJCSA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(Br)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(Br)=C1)=C1F QBLSBTDQYOUKCK-NHOCJEJCSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 230000003228 microsomal effect Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- OFBHRFQOAARPHM-ONEGZZNKSA-N (E)-4-bromo-N,N-dimethylbut-2-enamide Chemical compound CN(C)C(=O)\C=C\CBr OFBHRFQOAARPHM-ONEGZZNKSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CFPBYGKISUKURJ-UHFFFAOYSA-N 3h-quinolin-2-one Chemical compound C1=CC=CC2=NC(=O)CC=C21 CFPBYGKISUKURJ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NNVATAMETWDYJL-SNVBAGLBSA-N CC(C)CN[C@H](C)CC1=CC=CC(N2)=C1OC2=O Chemical compound CC(C)CN[C@H](C)CC1=CC=CC(N2)=C1OC2=O NNVATAMETWDYJL-SNVBAGLBSA-N 0.000 description 3
- MUGHAIJONDZTLK-DGIBIBHMSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC1CNC1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC1CNC1)=C1)=C1F MUGHAIJONDZTLK-DGIBIBHMSA-N 0.000 description 3
- YDBODRYRYOFBAE-YLNUKYHNSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(O[C@@H]1CN(CCCF)CC1)=C1)=C1OC Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(O[C@@H]1CN(CCCF)CC1)=C1)=C1OC YDBODRYRYOFBAE-YLNUKYHNSA-N 0.000 description 3
- VHAZOQNWKPBGQB-FEERPNRMSA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(Br)=C1)=C1OC Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(Br)=C1)=C1OC VHAZOQNWKPBGQB-FEERPNRMSA-N 0.000 description 3
- AZSZZPKNQRRJRD-UHFFFAOYSA-N O=C(C1=CC=CC(NCCBr)=C1C1)N1C(CCC(N1)=O)C1=O Chemical compound O=C(C1=CC=CC(NCCBr)=C1C1)N1C(CCC(N1)=O)C1=O AZSZZPKNQRRJRD-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 2
- OWUTXBIONAXKAK-UHFFFAOYSA-N 2-[3-(fluoromethyl)azetidin-1-yl]ethanol Chemical compound OCCN1CC(CF)C1 OWUTXBIONAXKAK-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- YMXQYZABFWVXEK-UHFFFAOYSA-N 4-bromo-2-methoxybenzaldehyde Chemical compound COC1=CC(Br)=CC=C1C=O YMXQYZABFWVXEK-UHFFFAOYSA-N 0.000 description 2
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 2
- LHTQHBZJSVUNBG-UHFFFAOYSA-N 7-bromo-3h-1,3-benzoxazol-2-one Chemical compound BrC1=CC=CC2=C1OC(=O)N2 LHTQHBZJSVUNBG-UHFFFAOYSA-N 0.000 description 2
- GBDQCRAZCZBZKS-BMSYQSAWSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N1CCN(C/C=C/C(N(C)C)=O)CC1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N1CCN(C/C=C/C(N(C)C)=O)CC1)=C1)=C1F GBDQCRAZCZBZKS-BMSYQSAWSA-N 0.000 description 2
- QVNJGSBVHXOOSN-FKUBTJATSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC1CN(C/C=C/C(N(C)C)=O)C1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC1CN(C/C=C/C(N(C)C)=O)C1)=C1)=C1F QVNJGSBVHXOOSN-FKUBTJATSA-N 0.000 description 2
- IXYZROXOPMJVIT-CSTKLKAISA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(O[C@H](CC1)CN1C(C=C)=O)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(O[C@H](CC1)CN1C(C=C)=O)=C1)=C1F IXYZROXOPMJVIT-CSTKLKAISA-N 0.000 description 2
- OWFYPCFTYHWFCM-ABKXIKBNSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1Br Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1Br OWFYPCFTYHWFCM-ABKXIKBNSA-N 0.000 description 2
- CTMZBLMQRQEDKV-VFNWGFHPSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1OCCN1CCNCC1 Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1OCCN1CCNCC1 CTMZBLMQRQEDKV-VFNWGFHPSA-N 0.000 description 2
- GGWOLJDQPURZHX-CGSMKXTHSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(O[C@@H]1CNCC1)=C1)=C1OC Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(O[C@@H]1CNCC1)=C1)=C1OC GGWOLJDQPURZHX-CGSMKXTHSA-N 0.000 description 2
- KPJBMJFCALGAJG-SSDOTTSWSA-N C[C@H](CC1=CC=CC(N2)=C1OC2=O)NCC(F)(F)F Chemical compound C[C@H](CC1=CC=CC(N2)=C1OC2=O)NCC(F)(F)F KPJBMJFCALGAJG-SSDOTTSWSA-N 0.000 description 2
- 101100074846 Caenorhabditis elegans lin-2 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100497386 Mus musculus Cask gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- APCBTRDHCDOPNY-ZETCQYMHSA-N tert-butyl (3s)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](O)C1 APCBTRDHCDOPNY-ZETCQYMHSA-N 0.000 description 2
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 2
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- WLRIREROKRGVTD-UHFFFAOYSA-N 1,5-diazacycloundec-5-ene Chemical compound C1CCNCCCN=CCC1 WLRIREROKRGVTD-UHFFFAOYSA-N 0.000 description 1
- QJVZTGCMNXMFRW-UHFFFAOYSA-N 1-(3-fluoropropyl)azetidin-3-amine Chemical compound NC1CN(CCCF)C1 QJVZTGCMNXMFRW-UHFFFAOYSA-N 0.000 description 1
- YNAVXXWOEVPHGM-UHFFFAOYSA-N 1-(3-fluoropropyl)azetidine Chemical compound FCCCN1CCC1 YNAVXXWOEVPHGM-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- CWWYEELVMRNKHZ-UHFFFAOYSA-N 2,3-dimethylbut-2-enamide Chemical compound CC(C)=C(C)C(N)=O CWWYEELVMRNKHZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LOBRHADLNRMHOO-UHFFFAOYSA-N 2-amino-6-bromophenol Chemical compound NC1=CC=CC(Br)=C1O LOBRHADLNRMHOO-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- KYBBNISHBZGENY-UHFFFAOYSA-N 3-(fluoromethyl)azetidine;hydrochloride Chemical compound Cl.FCC1CNC1 KYBBNISHBZGENY-UHFFFAOYSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- YLCGDHFJQQKIBG-UHFFFAOYSA-N 3-benzyl-1,3-benzoxazol-2-one Chemical compound O=C1OC=2C=CC=CC=2N1CC1=CC=CC=C1 YLCGDHFJQQKIBG-UHFFFAOYSA-N 0.000 description 1
- LYWIEFZAJGWPJC-UHFFFAOYSA-N 3a,4,5,9b-tetrahydro-3H-[1,3]oxazolo[4,5-h]isoquinolin-2-one Chemical compound O=C1NC2CCc3ccncc3C2O1 LYWIEFZAJGWPJC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CZGVAISJIQNQEJ-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzaldehyde Chemical compound FC1=CC(Br)=CC(F)=C1C=O CZGVAISJIQNQEJ-UHFFFAOYSA-N 0.000 description 1
- QGFYFOHMBDMGBZ-UHFFFAOYSA-N 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 QGFYFOHMBDMGBZ-UHFFFAOYSA-N 0.000 description 1
- LUJBEFQVVXDCPL-UHFFFAOYSA-N 5-bromo-3-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC(Br)=CN=C1C=O LUJBEFQVVXDCPL-UHFFFAOYSA-N 0.000 description 1
- WJFAWSUSKWTMSS-UHFFFAOYSA-N 5-bromo-3-methoxypyridine-2-carbaldehyde Chemical compound COC1=CC(Br)=CN=C1C=O WJFAWSUSKWTMSS-UHFFFAOYSA-N 0.000 description 1
- UHYJMVVKYRZJKO-UHFFFAOYSA-N C(=O)OC(C)(C)C.NC1CNC1 Chemical compound C(=O)OC(C)(C)C.NC1CNC1 UHYJMVVKYRZJKO-UHFFFAOYSA-N 0.000 description 1
- ADYFQOWNZHTKPO-WYRIXSBYSA-N CC(C)CN([C@H](C)CC(C1=CC=C2N3)=C2OC3=O)[C@@H]1C(C(F)=CC(Br)=C1)=C1F Chemical compound CC(C)CN([C@H](C)CC(C1=CC=C2N3)=C2OC3=O)[C@@H]1C(C(F)=CC(Br)=C1)=C1F ADYFQOWNZHTKPO-WYRIXSBYSA-N 0.000 description 1
- UJPIXDMILOQNMR-JLKRBFOBSA-N CC(C)CN([C@H](C)CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)[C@@H]1C(C(F)=CC(Br)=C1)=C1F Chemical compound CC(C)CN([C@H](C)CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)[C@@H]1C(C(F)=CC(Br)=C1)=C1F UJPIXDMILOQNMR-JLKRBFOBSA-N 0.000 description 1
- RALIHKJIIZDPOJ-GLEZIHRCSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=C1)=NC=C1Br Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=C1)=NC=C1Br RALIHKJIIZDPOJ-GLEZIHRCSA-N 0.000 description 1
- ZPHJRBMRSHWMQO-DMZKTXOQSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N(C1)CC1NCCCF)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N(C1)CC1NCCCF)=C1)=C1F ZPHJRBMRSHWMQO-DMZKTXOQSA-N 0.000 description 1
- IUFDXTNXXSKWHJ-PEBXRYMYSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N1CC2(CN(CCF)C2)C1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N1CC2(CN(CCF)C2)C1)=C1)=C1F IUFDXTNXXSKWHJ-PEBXRYMYSA-N 0.000 description 1
- LPTFDZNFYFCRHX-ODXCJYRJSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N1CC2(CNC2)C1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(N1CC2(CNC2)C1)=C1)=C1F LPTFDZNFYFCRHX-ODXCJYRJSA-N 0.000 description 1
- DSLKOEBAXAZHPZ-IPQOISQHSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC(C1)CN1C(C=C)=O)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC(C1)CN1C(C=C)=O)=C1)=C1F DSLKOEBAXAZHPZ-IPQOISQHSA-N 0.000 description 1
- DHCPXNCQYIQLRJ-DMZKTXOQSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC1CN(CCCF)C1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(NC1CN(CCCF)C1)=C1)=C1F DHCPXNCQYIQLRJ-DMZKTXOQSA-N 0.000 description 1
- OTUCXEPJJMIEEA-DMZKTXOQSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(OC1CN(CCCF)C1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(OC1CN(CCCF)C1)=C1)=C1F OTUCXEPJJMIEEA-DMZKTXOQSA-N 0.000 description 1
- IXYZROXOPMJVIT-XXAQJILISA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(O[C@@H](CC1)CN1C(C=C)=O)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=CC(O[C@@H](CC1)CN1C(C=C)=O)=C1)=C1F IXYZROXOPMJVIT-XXAQJILISA-N 0.000 description 1
- IVCUGJNYENKXBN-PEBXRYMYSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1NC1CN(CCCF)C1 Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1NC1CN(CCCF)C1 IVCUGJNYENKXBN-PEBXRYMYSA-N 0.000 description 1
- RANYMAWEKINGMQ-ZMZPIMSZSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1NC1CNC1 Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1NC1CNC1 RANYMAWEKINGMQ-ZMZPIMSZSA-N 0.000 description 1
- NNESWIRZVGYNHC-UHYGZKCKSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1O[C@@H]1CNCC1 Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=C1)=NC=C1O[C@@H]1CNCC1 NNESWIRZVGYNHC-UHYGZKCKSA-N 0.000 description 1
- WJSUJTIFAMZXCH-QGHHPUGFSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(Br)=C1)=C1OC Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(Br)=C1)=C1OC WJSUJTIFAMZXCH-QGHHPUGFSA-N 0.000 description 1
- SEBZLXZZBUZOKE-KOSHJBKYSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(N=C1)=CC=C1OCCN(CC1)CCN1C(OC(C)(C)C)=O Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(N=C1)=CC=C1OCCN(CC1)CCN1C(OC(C)(C)C)=O SEBZLXZZBUZOKE-KOSHJBKYSA-N 0.000 description 1
- SWHZAFAKKRZATJ-MYYSRTQBSA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC2(CC2)F)[C@@H]1C(C(F)=CC(NC1CN(CCCF)C1)=C1)=C1F Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC2(CC2)F)[C@@H]1C(C(F)=CC(NC1CN(CCCF)C1)=C1)=C1F SWHZAFAKKRZATJ-MYYSRTQBSA-N 0.000 description 1
- HRYRFMPPLAOZFR-BLVKFPJESA-N C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC2(CC2)F)[C@@H]1C(C=CC(Br)=C1)=C1OC Chemical compound C[C@H](CC(C1=CC=C2N3)=C2OC3=O)N(CC2(CC2)F)[C@@H]1C(C=CC(Br)=C1)=C1OC HRYRFMPPLAOZFR-BLVKFPJESA-N 0.000 description 1
- DXNRBMISLMPIKV-NHRFMIRVSA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=C1)=NC=C1Br Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(F)=C1)=NC=C1Br DXNRBMISLMPIKV-NHRFMIRVSA-N 0.000 description 1
- HZZQIMMHNHIHIB-ZWVRTZEQSA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1Br Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1Br HZZQIMMHNHIHIB-ZWVRTZEQSA-N 0.000 description 1
- OHSZJFDOMOFSAY-VFHLRKMQSA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1NC1CN(CCCF)C1 Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C(OC)=C1)=NC=C1NC1CN(CCCF)C1 OHSZJFDOMOFSAY-VFHLRKMQSA-N 0.000 description 1
- JXNPOTKKDXRPBP-AJSRXKBESA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(NC1CN(CCCF)C1)=C1)=C1OC Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(NC1CN(CCCF)C1)=C1)=C1OC JXNPOTKKDXRPBP-AJSRXKBESA-N 0.000 description 1
- FNLFZVMOOXGOIX-URVCABAXSA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(O[C@@H](CC1)CN1C(OC(C)(C)C)=O)=C1)=C1OC Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(C=CC(O[C@@H](CC1)CN1C(OC(C)(C)C)=O)=C1)=C1OC FNLFZVMOOXGOIX-URVCABAXSA-N 0.000 description 1
- QQEAJQSMFAXJGK-BIRWAASSSA-N C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(N=C1)=CC=C1NC(C1)CN1C(OC(C)(C)C)=O Chemical compound C[C@H](CC(C1=CC=C2N3C(C4=CC=CC=C4)(C4=CC=CC=C4)C4=CC=CC=C4)=C2OC3=O)N(CC(F)(F)F)[C@@H]1C(N=C1)=CC=C1NC(C1)CN1C(OC(C)(C)C)=O QQEAJQSMFAXJGK-BIRWAASSSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910017906 NH3H2O Inorganic materials 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- ZXPSRPAUXQIYID-UHFFFAOYSA-N [N].[Na] Chemical compound [N].[Na] ZXPSRPAUXQIYID-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- AWLOVEGGARHZNN-QMMMGPOBSA-N butyl (3s)-3-hydroxypyrrolidine-1-carboxylate Chemical group CCCCOC(=O)N1CC[C@H](O)C1 AWLOVEGGARHZNN-QMMMGPOBSA-N 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- VMOWKUTXPNPTEN-UHFFFAOYSA-N n,n-dimethylpropan-2-amine Chemical compound CC(C)N(C)C VMOWKUTXPNPTEN-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- NFAKQWFVEAEEPG-ZCFIWIBFSA-N tert-butyl (4r)-4-methyl-2,2-dioxooxathiazolidine-3-carboxylate Chemical compound C[C@@H]1COS(=O)(=O)N1C(=O)OC(C)(C)C NFAKQWFVEAEEPG-ZCFIWIBFSA-N 0.000 description 1
- FQJRZOYTUCCBQR-UHFFFAOYSA-N tert-butyl 2-methylheptanoate Chemical compound CCCCCC(C)C(=O)OC(C)(C)C FQJRZOYTUCCBQR-UHFFFAOYSA-N 0.000 description 1
- VRXIOAYUQIITBU-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCO)CC1 VRXIOAYUQIITBU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N trimethylmethane Natural products CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to certain novel compounds, or pharmaceutically acceptable salts thereof, which possess anticancer activity and are therefore potentially useful in methods of treating the human or animal body.
- the present invention also relates to methods for the manufacture of the compounds, pharmaceutical compositions containing them and their use in methods of treatment, such as for the manufacture of medicaments for the prevention or treatment of cancer in warm-blooded animals such as humans, including For the prevention or treatment of estrogen receptor-dependent or estrogen receptor-mediated diseases.
- the present invention also relates to compounds that are selective down-modulators of the estrogen receptor.
- Estrogen receptor belongs to the steroid hormone receptor, including two subtypes, ER ⁇ and ER ⁇ . ER is involved in the regulation and development of the female reproductive tract; in cancers such as breast cancer, tumor growth is related to the action of estrogen and ER receptors, for example, the expression of ER is elevated in most breast cancer patients.
- SERMs selective estrogen receptor modulators
- WO2017/182493A1 also discloses a SERM compound.
- the inventors of the present invention found that the compound represented by the formula (I) has the basic structure of tetrahydrooxazoloisoquinolin-one, which has significant ER degradation activity, and therefore unexpectedly has significantly better properties than the prior art Compounds are known for their ER inhibitory activity; such compounds also have excellent metabolic stability. Therefore, the compounds of the present invention can be used for the treatment of estrogen receptor-dependent or estrogen receptor-mediated diseases, thereby completing the present invention.
- the present invention relates to the following.
- One aspect of the present invention provides a compound of formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof:
- Z 1 is selected from CR a R b , C(O) and a bond
- Z 2 is selected from O, S, NR c , C(O) and bonds, or C 1 -C 6 alkylene, O-(C 1 -C optionally substituted with one or more of the same or different R d 6 alkylene) or NH-(C 1 -C 6 alkylene);
- Cy 1 is selected from C 6-14 arylene, C 3-8 cycloalkylene, C 5-14 heteroarylene, C 3-14 heterocycloalkylene, C 3-14 heterocycloalkenylene, each of which is optionally substituted with a group selected from the group consisting of halogen atoms, hydroxy, amino, cyano and C 1-6 alkyl or C 1-6 alkoxy optionally substituted with halogen atoms;
- Cy 2 is selected from bond, C 3-10 cycloalkylene, C 3-14 heterocycloalkylene, each of which is optionally substituted with a group selected from the group consisting of halogen atoms (including F, Cl, Br or I atoms) ), hydroxyl, amino, cyano, and C 1-6 alkyl or C 1-6 alkoxy optionally substituted by halogen atoms;
- halogen atoms including F, Cl, Br or I atoms
- R 1 and R 2 are each independently H, halogen atom, hydroxyl, amino, cyano, C 1-6 alkyl, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkenylamino , C 3 -C 8 cycloalkyl, said C 1-6 alkyl, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkenylamino or C 3 -C 8 cycloalkyl optionally substituted by one or more groups selected from halogen atoms, hydroxy, amino, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, cyano or oxo;
- R 4 is H, halogen atom, hydroxyl, amino, cyano, C 1-6 alkyl, C 1-6 alkylamino, amino C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkene amino, C 3 -C 8 cycloalkyl, the C 1-6 alkyl, C 1-6 alkylamino, amino C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkenyl Amino or C 3 -C 8 cycloalkyl is optionally replaced by one or more selected from halogen atoms, hydroxyl, amino, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, cyano, oxo group, C 6-14 aryl, C 5-14 heteroaryl, C 3-14 heterocycloalkylene or
- R 4 is H, halogen atom, hydroxyl, amino, cyano, C 1-6 alkyl, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkenylamino, C 3 -C 8 cycloalkyl, said C 1-6 alkyl, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkenylamino or C 3 -C 8 cycloalkyl are optionally Substituted with one or more groups selected from halogen atom, hydroxyl, amino, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, cyano or oxo;
- R 3 is -(CR e R f ) m -CR 31 R 32 R 33 , wherein m is 1, 2 or 3;
- R 31 , R 32 and R 33 are independently selected from: H, a C 1-6 alkyl group, a halogen atom, a cyano group, and R 31 and R 32 may together form a C 3-8 cycloalkylene group, the C 1-8 6 alkyl and C 3-8 cycloalkylene are optionally substituted by hydroxyl, cyano, amino or halogen atoms;
- R a , R b , R c , R d , Re and R f are each independently H, a halogen atom, a hydroxyl group, an amino group, a cyano group, a C 1-6 alkyl group optionally substituted with a halogen atom.
- heteroaryl/heteroarylene, heterocycloalkyl/heterocycloalkylene, heterocycloalkenyl/heterocycloalkenyl contain 1-4 selected from N, O, S
- the heteroatoms are used as ring constituent atoms.
- the cycloalkyl/cycloalkylene, heterocycloalkyl/heterocycloalkylene, heterocycloalkenyl/heterocycloalkenylene may be monocyclic, bicyclic or tricyclic (preferably monocyclic or bicyclic) ring systems, wherein bicyclic or tricyclic ring systems include spiro, bridged or fused rings.
- the aryl/arylene and heteroaryl/heteroarylene may be monocyclic, fused bicyclic or fused tricyclic (preferably monocyclic or fused bicyclic) ring systems, and wherein the fused bicyclic or The fused tricyclic ring system may contain non-aromatic ring structures.
- the halogen atoms are selected from F, Cl, Br or I atoms.
- Z 1 is selected from CR a R b , C(O) and a bond
- Z 2 is selected from O, S, NR c , C(O) and bonds, or C 1 -C 6 alkylene, O-(C 1 -C optionally substituted with one or more of the same or different R d 6 alkylene) or NH-(C 1 -C 6 alkylene);
- Cy 1 is selected from C 6-14 arylene (preferably C 6-10 arylene) and C 5-14 heteroarylene (preferably C 5-10 heteroarylene), each of which is optionally selected from the following The group substitution of: halogen atom, and C 1-6 alkyl or C 1-6 alkoxy optionally substituted by halogen atom;
- Cy 2 is selected from bonds, C 3-10 cycloalkylene (preferably C 3-8 cycloalkylene), C 3-14 heterocycloalkylene (preferably C 3-10 heterocycloalkylene);
- R 1 and R 2 are each independently H or a C 1-6 alkyl group, and the C 1-6 alkyl group is optionally substituted by one or more groups selected from halogen atoms, hydroxyl groups or cyano groups;
- R 3 is -(CR e R f ) m -CR 31 R 32 R 33 , wherein m is 1, 2 or 3;
- R 31 , R 32 and R 33 are independently selected from: H, a C 1-6 alkyl group, a halogen atom, a cyano group, and R 31 and R 32 may together form a C 3-8 cycloalkylene group, the C 1-8 6 alkyl and C 3-8 cycloalkylene are optionally substituted by hydroxyl, cyano, amino or halogen atoms;
- R a , R b , R c , R d , Re , R f are each independently H or a halogen atom
- R 4 is C 1-6 alkyl, C 1-6 alkylamino, amino C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkenylamino, C 3 -C 8 cycloalkyl,
- the C 1-6 alkyl, C 1-6 alkylamino, amino C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkenylamino or C 3 -C 8 cycloalkyl are optional by one or more selected from halogen atom, hydroxyl, amino, C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, cyano, oxo and
- R 4 is C 1-6 alkyl, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkenylamino, C 3 -C 8 cycloalkyl, the C 1- 6 alkyl, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkenylamino, or C 3 -C 8 cycloalkyl optionally by one or more selected from halogen atoms, hydroxyl, amino , C 1-6 alkylamino, (C 1-6 alkyl) 2 amino, cyano or oxo group substitution.
- Z 1 is the key
- Z 2 is selected from -O-CH 2 -CH 2 -, -O-CH 2 -, -NH-CH 2 -CH 2 -, -NH-CH 2 -, -NH- or -O-;
- Cy 1 is a C 6-10 arylene group (preferably phenyl) and a C 5-10 heteroarylene group (preferably pyridyl), which are optionally replaced by a halogen atom (preferably F) or a C 1-6 alkoxy group (preferably methoxy) substituted;
- Cy 2 is selected from bond, azetidine, pyrrolidylene, piperazinylene,
- R 1 is C 1-6 alkyl (preferably methyl);
- R 2 is H
- R 3 is -CH 2 -CR 31 R 32 R 33 ;
- R 31 , R 32 and R 33 are independently selected from: H, C 1-6 alkyl (preferably methyl) optionally substituted with hydroxy or halogen atom (preferably F), halogen atom (preferably F), cyano, and R 31 and R 32 may together form a C 3-8 cycloalkylene group (preferably cyclopropylidene) optionally substituted by a hydroxyl group or a halogen atom (preferably F);
- R 4 is optionally selected from halogen atom (preferably F), oxo group, C 1-6 alkylamino (preferably methylamino), (C 1-6 alkyl) 2 amino (preferably dimethylamino) ,and
- Cy 2 is selected from bond, azetidine, pyrrolidylene, and R 4 is optionally selected from halogen atom (preferably F), oxo, C 1-6 alkylamino (preferably methylamino) and (C 1-6 alkyl) 2 amino (preferably dimethylamino) groups substituted C 1-6 alkyl, C 1-6 alkylamino, C 2-6 alkenyl, C 2-6 alkenylamino.
- halogen atom preferably F
- oxo oxo
- C 1-6 alkylamino preferably methylamino
- C 1-6 alkyl 2 amino preferably dimethylamino
- Z 1 is the key
- Z 2 is selected from -NH- or -O-;
- Cy 1 is phenyl or pyridyl (preferably phenyl) optionally substituted with F or methoxy;
- Cy 2 is selected from azetidine, pyrrolidylene, piperazinylene;
- R 1 is methyl
- R 2 is H
- R 3 is -CH 2 -CR 31 R 32 R 33 ;
- R 31 and R 32 are each F, or R 31 and R 32 together form a cyclopropylene
- R 33 is selected from: H, hydroxymethyl, fluoromethyl, preferably selected from F, hydroxymethyl, fluoromethyl;
- R 4 is F-(CH 2 ) 3 -or
- Cy 2 is selected from azetidine and pyrrolidylene, and R 4 is F-(CH 2 ) 3 -.
- the compounds of formula (I) of the present invention are in the form of stereoisomers, eg, the carbon at position 1 of the tetrahydroisoquinoline ring (ie, the carbon to which Z is attached) may be in the S configuration , and/or the carbon at position 3 (ie, the carbon to which R 1 is attached) may be in the R configuration.
- the present invention relates to the following compounds or stereoisomers or pharmaceutically acceptable salts thereof:
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising any one or more of the foregoing compounds of the present invention, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the present invention relates to the use of a compound of the present invention in the manufacture of a medicament for the treatment of an estrogen receptor-dependent or estrogen receptor-mediated disease in a mammal.
- Step 3 Synthesis of (R)-7-2-aminopropyl)(2,2,2-trifluoroethyl-3-tritylbenzo[d]oxazol-2(3H)-one
- Step 6 3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)-3-trityl-2, 3,6,7,8,9-Six Synthesis of Hydroxazolo[5,4-f]isoquinolin-6yl)pyridin-3-yl)amino)azetidine-1-carboxylic acid tert-butyl ester
- Step 7 (6S,8R)-6-(5-(azetidine-3-amino)pyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl yl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Trifluoroacetic acid (9.00 mL) and water (1.00 mL) were added to 3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2) at 0°C -Trifluoroethyl)-3-trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6yl)pyridin-3-yl ) amino) azetidine-1-carboxylic acid tert-butyl ester (120 mg, 154 ⁇ mol, 1 eq), the mixture was reacted at 20° C. for 2 hours, and the completion of the reaction was monitored by TLC.
- Step 8 (6S,8R)-6-(5-((1-(3-fluoropropane)azetidin-3-yl)amino)pyridin-2-yl)-8-methyl -Synthesis of 7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one (compound 5)
- Step 1 (S)-3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)-3-trityl Base-2,3,6,7,8,9- Synthesis of tert-butyl hexahydrooxazolo[5,4-f]isoquinolin-6-yl)pyridin-3-yl)oxy)pyrrolidine-1-carboxylate
- Trifluoroacetic acid (1.54 g, 13.4 mmol, 997 uL, 87.3 eq) was added to (S)-3-((6-((6S,8R)-8-methane dissolved in dichloromethane (2 mL) at 0 °C yl-2-oxo-7-(2,2,2-trifluoroethyl)-3-trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4 -f] isoquinolin-6-yl)pyridin-3-yl)oxy)pyrrolidine-1-carboxylic acid tert-butyl ester (120 mg, 154 ⁇ mol, 1 eq) at 20°C for 2 hours, TLC and LCMS monitoring the reaction Finish.
- Step 1 (6S,8R)-6-(3,5-difluoro-4-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl) )-3-trityl -2,3,6,7,8,9-Hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenyl)-2,6-diazaspiro[3.3]heptane- Synthesis of tert-butyl 2-carboxylate to make
- Step 3 (6S,8R)-6-(2,6-difluoro-4-(6-(2-fluoroethyl)-2,6-diazaspiro[3.3]heptane-2-yl)benzene base)-8-methyl Synthesis of -7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Step 4 (6S,8R)-6-(2,6-difluoro-4-(6-(2-fluoroethyl)-2,6-diazaspiro[3.3]heptane-2-yl)benzene base)-8-methyl Resolution of -7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one ( Compound 8)
- Example 13-15 were synthesized; the compound in Example 5, step 3, namely “(R) -7-2-Aminopropyl)(2,2,2-trifluoroethyl-3-tritylbenzo[d]oxazol-2(3H)-one ⁇ as starting material, the following Example 10 was synthesized -12, 16, 18, 25; the compound of step 4 in Example 1 is -(R)-7-(2-aminopropyl)-3-tritylbenzo[d]o
- Step 3 (6S,8R)-6-(4-((1-(3-Fluoropropyl)azetidin-3-yl)amino)-2-methoxyphenyl)-8-methyl yl-7-(2,2,2-trifluoroethyl)-3-trityl-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinoline-2( Synthesis of 3H)-ketone
- Trifluoroacetic acid (15.4 g, 135 mmol) and (6S,8R)-6-(4-((1-(3-fluoropropyl)azetidin-3-yl)amino)-2-methoxy phenyl)-8-methyl-7-(2,2,2-trifluoroethyl)-3-trityl-6,7,8,9-tetrahydrooxazolo[5,4- f]
- Isoquinolin-2(3H)-one (1 g, 1.31 mmol) was dissolved in water (1 mL), and the reaction solution was reacted at 20° C. under nitrogen protection for 1 hour. The end of the reaction was detected by LCMS.
- Step 6 3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)-3-trityl-2, 3,6,7,8,9-Hexahydrooxazolo[5,4-f]isoquinolin-6yl)pyridin-3-yl)amino)azetidine-1-carboxylate tert-butyl ester synthesis
- Step 7 (6S,8R)-6-(5-(azetidin-3-ylamino)pyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl yl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Trifluoroacetic acid (9.00 mL) and water (1.00 mL) were added to 3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2) at 0°C -Trifluoroethyl)-3-trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6yl)pyridin-3-yl ) amino) azetidine-1-carboxylic acid tert-butyl ester (120 mg, 154 umol, 1 eq), the mixture was reacted at 20° C. for 2 hours, and the completion of the reaction was monitored by TLC.
- Step 8 (6S,8R)-6-(5-((1-(3-fluoropropane)azetidin-3-yl)amino)pyridin-2-yl)-8-methyl-7- Synthesis of (2,2,2-trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Step 4 (6S,8R)-6-(3-Fluoro-5-((1-(3-Fluoropropyl)azetidin-3-yl)amino)pyridin-2-yl)-8- Synthesis of methyl-7-(2,2,2-trifluoromethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Trifluoroacetic acid (2.02 g, 17.6 mmol) was dissolved in water (0.05 mL) and (6S,8R)-6-(3-fluoro-5-((1-(3-fluoropropyl)azetidine) was added Alkyl-3-yl)amino)pyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-3-trityl-6,7,8,9- In tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one (120 mg, 138 umol), the reaction was carried out at 20°C for 5 hours under nitrogen protection. LCMS detected the end of the reaction.
- Step 5 (6S,8R)-6-(3-Fluoro-5-((1-(3-Fluoropropyl)azetidin-3-yl)amino)pyridin-2-yl)-8- Synthesis of methyl-7-(2,2,2-trifluoromethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Step 1 (6S,8R)-6-(5-bromo-3-methoxypyridin-2-yl)-8-methyl-7-(2,2,2-trifluoroethyl)-6, Synthesis of 7,8,9-Tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Step 3 (6S,8R)-6-(5-((1-(3-Fluoropropyl)azetidin-3-yl)amino)-3-methoxypyridin-2-yl) -8-Methyl-7-(2,2,2-trifluoroethyl)-3-trityl-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinoline Synthesis of Lin-2(3H)-ones
- Step 1 (S)-3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)-3-trityl tert-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)pyridin-3-yl)oxy)pyrrolidine-1-carboxylic acid Synthesis of Butyl Ester
- Trifluoroacetic acid (1.54 g, 13.4 mmol, 997 uL, 87.3 eq) was added to (S)-3-((6-((6S,8R)-8-methane dissolved in dichloromethane (2 mL) at 0 °C yl-2-oxo-7-(2,2,2-trifluoroethyl)-3-trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4 -f] isoquinolin-6-yl)pyridin-3-yl)oxy)pyrrolidine-1-carboxylate tert-butyl ester (120mg, 154umol, 1eq) at 20°C for 2 hours, monitored by TLC and LCMS The reaction is complete.
- Step 1 (S)-3-(3-methoxy-4-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)- 3-Trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenoxy)pyrrolidine-1-carboxylic acid tert.
- Step 3 (6S,8R)-6-(4-(((S)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methoxyphenyl)-8 -Methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one synthesis
- Step 2 (6S,8R)-7-((1-Fluorocyclopropyl)methyl)-6-(4-((1-(3-Fluoropropyl)azetidin-3-yl) ) Amino)-2-methoxyphenyl)-8-methyl-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Step 1 3-((3,5-Difluoro-4-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)-3- Trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenyl)amino)azetidine-1- Synthesis of tert-butyl formate
- Step 2 (6S,8R)-6-(4-(azetidin-3-ylamino)-2,6-difluorophenyl)-8-methyl-7-(2,2,2 Synthesis of -trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Trifluoroacetic acid (15.5 g, 135 mmol) was dissolved in water (1 mL) and 3-((3,5-difluoro-4-((6S,8R)-8-methyl-2-oxo-7- (2,2,2-Trifluoroethyl)-3-trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinoline-6- (400 mg, 493 umol) in tert-butyl) phenyl) amino) azetidine-1-carboxylate (400 mg, 493 umol), and reacted under nitrogen protection at 20°C for 2 hours.
- LCMS detected the end of the reaction.
- Step 3 (E)-4-(3-((3,5-difluoro-4-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-tri Fluoroethyl)-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenyl)amino)azetidine-1 -base)-N,N-dimethylbut-2-enamide synthesis
- Example 36 (6S,8R)-6-(4-((1-Acryloylazetidin-3-yl)amino)-2,6-difluorophenyl)-8-methyl-7 -(2,2,2-Trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one (Compound 36)
- Step 1 (6S,8R)-6-(4-((1-acryloylazetidin-3-yl)amino)-2,6-difluorophenyl)-8-methyl-7- Synthesis of (2,2,2-trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Step 1 (R)-3-(3,5-difluoro-4-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl) -3-Trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenoxy)pyrrolidine-1-carboxylic acid Synthesis of tert-butyl ester
- Trifluoroacetic acid (6.16 g, 54.0 mmol) was dissolved in water (0.4 mL) and (R)-3-(3,5-difluoro-4-((6S,8R)-8-methyl-2- Oxo-7-(2,2,2-trifluoroethyl)-3-trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]iso quinolin-6-yl)phenoxy)pyrrolidine-1-carboxylate tert-butyl ester (503mg, 609umol), react under nitrogen protection at 20°C for 2 hours. LCMS detected the end of the reaction.
- Step 3 (E)-4-((R)-3-((3,5-difluoro-4-((6S,8R)-8-methyl-2-oxo-7-(2,2, 2-Trifluoroethyl)-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenoxy)pyrrolidin-1-yl Synthesis of )-N,N-dimethylbut-2-enamide
- Step 1 (6S,8R)-6-(4-(((R)-1-acryloylpyrrolidin-3-yl)oxy)-2,6-difluorophenyl)-8-methyl- Synthesis of 7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydrooxazolo[5,4-f]isoquinolin-2(3H)-one
- Step 1 4-(3,5-Difluoro-4-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)-3-tri Synthesis of Benzyl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenyl)piperazine-1-carboxylic acid tert-butyl ester
- Trifluoroacetic acid (12.3 g, 107 mmol) was dissolved in water (0.1 mL) and 4-(3,5-difluoro-4-((6S,8R)-8-methyl-2-oxo-7- (2,2,2-Trifluoroethyl)-3-trityl-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinoline-6- (413 mg, 500 umol) in tert-butyl) phenyl) piperazine-1-carboxylate (413 mg, 500 umol), react under nitrogen protection at 20°C for 2 hours. LCMS detected the end of the reaction.
- Step 3 (E)-4-(4-(3,5-difluoro-4-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoro) ethyl)-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)phenyl)piperazin-1-yl)-N,N - Synthesis of dimethylbut-2-enamide
- Example 42 3-(4-((2-(4-(3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-tri Fluoroethyl)-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)pyridin-3-yl)oxy)ethyl)piperidine Azin-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 42)
- Step 1 4-(2-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoroethyl)-2,3,6, Synthesis of 7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)pyridin-3-yl)oxy)ethyl)piperazine-1-carboxylic acid tert-butyl ester
- Step 3 Synthesis of 3-(4-((2-bromoethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
- Step 4 3-(4-((2-(4-(3-((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-trifluoro) ethyl)-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)pyridin-3-yl)oxy)ethyl)piperazine Synthesis of -1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
- Example 43 Similar to the synthetic route of the previous Example 42, the following Example 43 was synthesized by selecting the corresponding reactants and the synthetic methods known to those skilled in the art.
- Example 43 3-(4-((2-(4-(3-(((6-((6S,8R)-8-methyl-2-oxo-7-(2,2,2-tris) Fluoroethyl)-2,3,6,7,8,9-hexahydrooxazolo[5,4-f]isoquinolin-6-yl)pyridin-3-yl)oxy)propyl)piperidine Azin-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (Compound 43)
- AZD9496 catalog number: HY-12870
- AZD9833 catalog number: HY-136255
- tamoxifen catalog number: HY-13757A
- Comparative Compound 1 chemical structure: ( 6S,8R)-6-(2,6-Difluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-7-(2 -Fluoro-2-methylpropyl)-8-methyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinoline) using the example in WO2017/182493A1 1 prepared by the method.
- X is the "665 value to 615 value” for each concentration.
- Min is the mean value of "665 to 615" with the addition of 0.2 mM positive control compound and 5 nl of 3 nM (1.5 nM) estradiol.
- Max is the "665 value to 615 value” average of DMSO and 5nl 3nM (1.5nM) estradiol. Import the data into Graphpad Prism and use Log(agonist) vs.response--variable slope for curve fitting.
- Example 1 9.00 100.2
- Example 9 21.6 100.1
- Example 12 15.6 100.3
- Example 14 40.3 100.2
- Example 25 11.4 100.8
- Example 30 8.85 99.8
- Example 31 45.6 100.9
- Example 32 14.7 100.3
- Example 33 11.8 99.9
- Example 34 19.4 100.2 AZD9833 62.0 99.8 Tamoxifen 578.1 100.4
- Human breast cancer cells MCF-7 (HTB-22, purchased from ATCC) were seeded in 96-well plates in medium containing 10% FBS (Gibco, 10099-141), 1% pyruvate (Sigma, S8636), 1% Non-essential amino acids (Sigma, M7145) in MEM (Hyclone, SH30024.01B) medium, seeded at a density of 4,000 cells/well, and cells were cultured at 37°C, 5% CO 2 .
- Compounds were prepared as 20 mM stock solutions, serially diluted in 100% DMSO (Sigma, D2650) to a final concentration of 1000, and then diluted 20-fold in medium containing 2% FBS.
- Example 1 0.39
- Example 9 0.19
- Example 10 0.20
- Example 11 0.38
- Example 12 0.49
- Example 13 0.30
- Example 14 0.44
- Example 16 0.80
- Example 25 0.24
- Example 26 0.55
- Example 27 1.63
- Example 28 0.40
- Example 29 0.71
- Example 30 0.21
- Example 31 0.85
- Example 32 0.39
- Example 33 0.39
- Example 34 0.19
- Example 35 0.82
- Example 37 0.61
- Example 39 0.49
- Example 43 0.69 AZD9496* 3.84 AZD9833* 2.45 Tamoxifen* 274.50 Comparative Compound 1* 2.68
- This test example uses ER ⁇ DuoSet IC ELISA Kit (R&D, DYC5715) to detect the degradation of ER ⁇ by compounds.
- human breast cancer cells MCF-7 (source as above) were inoculated in 24-well plates; the medium was 10% activated carbon-treated FBS (Tocyto, UT61204), 1% pyruvate, and 1% non-essential amino acids.
- FBS Tocyto, UT61204
- 1% pyruvate 1% non-essential amino acids.
- MEM medium seeding density was 150,000 cells/well; cells were cultured at 37°C, 5% CO2 for 24 hours.
- the compounds to be tested were serially diluted and added to 24-well plates containing cells. Cells were incubated for 24 hours at 37°C, 5% CO2. ERa capture antibody was diluted to 1 ⁇ g/ml with PBS (Corning, 21-040-CVR), added at 100 ⁇ L/well to a 96-well plate, sealed and coated overnight at room temperature.
- the coated 96-well plate was washed three times with PBS, 300 ⁇ L of blocking solution (R&D, DY995) was added to each well, and the plate was blocked at room temperature for 1 hour.
- the 24-well plate was washed once with PBS, the residual liquid was removed, and 60 ⁇ L of lysate (6M urea (Sigma, U5378), 1 mM EDTA (Sigma, E9884), 0.5% TritonX-100 (Sigma, T8787), 1 mM urea (Sigma, T8787), 1 mM lysis buffer) was added to each well.
- the T0 plate sample was first added with 600 ⁇ L of stop solution (acetonitrile: methanol (95:5, v/v) solution containing 100 ng/mL tolbutamide (Sigma, T0891)), and then NADPH regeneration system working solution was added.
- stop solution acetonitrile: methanol (95:5, v/v) solution containing 100 ng/mL tolbutamide (Sigma, T0891)
- test product supernatant was diluted into 200 ⁇ L of aqueous solution containing 0.3% formic acid for LC-MS/MS analysis, and 100 ⁇ L of the reference product supernatant was diluted to 300 ⁇ L of pure water was used for LC-MS/MS analysis and calculated according to the following formula:
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
物质 | 最终浓度(nM) | 工作浓度(nM) | 原液浓度(nM) |
GST-ERα-LBD | 2 | 4 | 20100 |
MAb抗GST-Eu | 2.5ng/孔 | 50nl/孔 | 50μg/ml |
物质 | 最终浓度(nM) | 工作浓度(nM) | 原液浓度(nM) |
生物素-SRC2 | 75 | 150 | 1000000 |
抗生蛋白链菌素-XL665 | 50ng/孔 | 50nl/孔 | 1mg/ml |
化合物 | IC 50(nM) | 最大抑制率 |
实施例1 | 9.00 | 100.2 |
实施例9 | 21.6 | 100.1 |
实施例10 | 7.80 | 100.2 |
实施例12 | 15.6 | 100.3 |
实施例14 | 40.3 | 100.2 |
实施例25 | 11.4 | 100.8 |
实施例26 | 58.4 | 100.4 |
实施例30 | 8.85 | 99.8 |
实施例31 | 45.6 | 100.9 |
实施例32 | 14.7 | 100.3 |
实施例33 | 11.8 | 99.9 |
实施例34 | 19.4 | 100.2 |
AZD9833 | 62.0 | 99.8 |
他莫昔芬 | 578.1 | 100.4 |
化合物 | IC 50(nM) |
实施例1 | 0.39 |
实施例9 | 0.19 |
实施例10 | 0.20 |
实施例11 | 0.38 |
实施例12 | 0.49 |
实施例13 | 0.30 |
实施例14 | 0.44 |
实施例16 | 0.80 |
实施例25 | 0.24 |
实施例26 | 0.55 |
实施例27 | 1.63 |
实施例28 | 0.40 |
实施例29 | 0.71 |
实施例30 | 0.21 |
实施例31 | 0.85 |
实施例32 | 0.39 |
实施例33 | 0.39 |
实施例34 | 0.19 |
实施例35 | 0.82 |
实施例37 | 0.61 |
实施例39 | 0.49 |
实施例43 | 0.69 |
AZD9496* | 3.84 |
AZD9833* | 2.45 |
他莫昔芬* | 274.50 |
对比化合物1* | 2.68 |
Claims (10)
- 式(I)的化合物,或其立体异构体或药学上可接受的盐:其中:Z 1选自CR aR b、C(O)和键;Z 2选自O、S、NR c、C(O)和键,或任选被一个或多个相同或不同的R d取代的C 1-C 6亚烷基、O-(C 1-C 6亚烷基)或NH-(C 1-C 6亚烷基);Cy 1选自C 6-14亚芳基、C 3-8亚环烷基、C 5-14亚杂芳基、C 3-14亚杂环烷基、C 3-14亚杂环烯基,其各自任选被选自以下的基团取代:卤素原子、羟基、氨基、氰基以及任选被卤素原子取代的C 1-6烷基或C 1-6烷氧基;Cy 2选自键、C 3-10亚环烷基、C 3-14亚杂环烷基,其各自任选被选自以下的基团取代:卤素原子(包括F、Cl、Br或I原子)、羟基、氨基、氰基以及任选被卤素原子取代的C 1-6烷基或C 1-6烷氧基;R 1、R 2各自独立地为H、卤素原子、羟基、氨基、氰基、C 1-6烷基、C 1-6烷基氨基、C 2-6烯基、C 2-6烯基氨基、C 3-C 8环烷基,所述C 1-6烷基、C 1-6烷基氨基、C 2-6烯基、C 2-6烯基氨基或C 3-C 8环烷基任选被一个或多个选自卤素原子、羟基、氨基、C 1-6烷基氨基、(C 1-6烷基) 2氨基、氰基或氧代基的基团取代;R 4为H、卤素原子、羟基、氨基、氰基、C 1-6烷基、C 1-6烷基氨基、氨基C 1-6烷基、C 2-6烯基、C 2-6烯基氨基、C 3-C 8环烷基,所述C 1-6烷基、C 1-6烷基氨基、氨基C 1-6烷基、C 2-6烯基、C 2-6烯基氨基或C 3-C 8环烷基任选被一个或多个选自卤素原子、羟基、氨基、C 1-6烷基氨基、(C 1-6烷基) 2氨基、氰基、氧代基、C 6-14芳基、C 5-14杂芳基、C 3-14亚杂环烷基或的基团取代;优选地,R 4为H、卤素原子、羟基、氨基、氰基、C 1-6烷基、C 1-6烷基氨基、C 2-6烯基、C 2-6烯基氨基、C 3-C 8环烷基,所述C 1-6烷基、C 1-6烷基氨基、C 2-6烯基、C 2-6烯基氨基或C 3-C 8环烷基任选被一个或多个选自卤素原子、羟基、氨基、C 1-6烷基氨基、(C 1-6烷基) 2氨基、氰基或氧代基的基团取代;R 3为-(CR eR f) m-CR 31R 32R 33,其中m为1、2或3;R 31、R 32和R 33独立选自:H、C 1-6烷基、卤素原子、氰基,且R 31和R 32可以共同形成C 3-8亚环烷基,所述C 1-6烷基和C 3-8亚环烷基任选被羟基、氰基、氨基或卤素原子取代;R a、R b、R c、R d、R e、R f各自独立地为H、卤素原子、羟基、氨基、氰基、任选被卤素原子取代的C 1-6烷基。
- 根据权利要求1所述的化合物,或其立体异构体或药学上可接受的盐,其中Z 1选自CR aR b、C(O)和键;Z 2选自O、S、NR c、C(O)和键,或任选被一个或多个相同或不同的R d取代的C 1-C 6亚烷基、O-(C 1-C 6亚烷基)或NH-(C 1-C 6亚烷基);Cy 1选自C 6-14亚芳基(优选C 6-10亚芳基)和C 5-14亚杂芳基(优选C 5-10亚杂芳基),其各自任选被选自以下的基团取代:卤素原子、以及任选被卤素原子取代的C 1-6烷基或C 1-6烷氧基;Cy 2选自键、C 3-10亚环烷基(优选C 3-8亚环烷基)、C 3-14亚杂环烷基(优选C 3-10亚杂环烷基);R 1、R 2各自独立地为H或C 1-6烷基,所述C 1-6烷基任选被一个或多个选自卤素原子、羟基或氰基的基团取代;R 3为-(CR eR f) m-CR 31R 32R 33,其中m为1、2或3;R 31、R 32和R 33独立选自:H、C 1-6烷基、卤素原子、氰基,且R 31和R 32可以共同形成C 3-8亚环烷基,所述C 1-6烷基和C 3-8亚环烷基任选被羟基、氰基、氨基或卤素原子取代;R a、R b、R c、R d、R e、R f各自独立地为H或卤素原子;R 4为C 1-6烷基、C 1-6烷基氨基、氨基C 1-6烷基、C 2-6烯基、C 2-6烯基氨基、C 3-C 8环烷基,所述C 1-6烷基、C 1-6烷基氨基、氨基C 1-6烷基、C 2-6烯基、C 2-6烯基氨基或C 3-C 8环烷基任选被一个或多个选自卤素原子、羟基、氨基、C 1-6烷基氨基、(C 1-6烷基) 2氨基、氰基、氧代基和的基团取代。
- 根据权利要求2所述的化合物,或其立体异构体或药学上可接受的盐,其中,R 4为C 1-6烷基、C 1-6烷基氨基、C 2-6烯基、C 2-6烯基氨基、C 3-C 8环烷基,所述C 1-6烷基、C 1-6烷基氨基、C 2-6烯基、C 2-6烯基氨基或C 3-C 8环烷基任选被一个或多个选自卤素原子、羟基、氨基、C 1-6烷基氨基、(C 1-6烷基) 2氨基、氰基或氧代基的基团取代。
- 根据权利要求1-3中任一项所述的化合物,或其立体异构体或药学上可接受的盐,其中Z 1为键;Z 2选自-O-CH 2-CH 2-、-O-CH 2-、-NH-CH 2-CH 2-、-NH-CH 2-、-NH-或-O-;Cy 1为C 6-10亚芳基(优选苯基)和C 5-10亚杂芳基(优选吡啶基),其任选被卤素原子(优选F)或C 1-6烷氧基(优选甲氧基)取代;Cy 2选自键、亚氮杂环丁基、亚吡咯烷基、亚哌嗪基、R 1为C 1-6烷基(优选甲基);R 2为H;R 3为-CH 2-CR 31R 32R 33;R 31、R 32和R 33独立选自:H、任选被羟基或卤素原子(优选F)取代的C 1-6烷基(优选甲基)、卤素原子(优选F)、氰基,且R 31和R 32可以共同形成任选被羟基或卤素原子(优选F)取代的C 3-8亚环烷基(优选亚环丙基);R 4为任选被选自卤素原子(优选F)、氧代基、C 1-6烷基氨基(优选甲基氨基)、(C 1-6烷基) 2氨基(优选二甲基氨基)、和的基团取代的C 1-6烷基、C 1-6烷基氨基、氨基C 1-6烷基、C 2-6烯基、C 2-6烯基氨基。
- 根据权利要求4所述的化合物,或其立体异构体或药学上可接受的盐,其中Cy 2选自键、亚氮杂环丁基、亚吡咯烷基,且R 4为任选被选自卤素原子(优选F)、氧代基、C 1-6烷基氨基(优选甲基氨基)和(C 1-6烷基) 2氨基(优选二甲基氨基)的基团取代的C 1-6烷基、C 1-6烷基氨基、C 2-6烯基、C 2-6烯基氨基。
- 根据权利要求6所述的化合物,或其立体异构体或药学上可接受的盐,其中Cy 2选自亚氮杂环丁基和亚吡咯烷基,且R 4为F-(CH 2) 3-。
- 一种药物组合物,其包含根据权利要求1-8中任一项所述的化合物或其立体异构体或药学上可接受的盐,以及药学上可接受的载体。
- 根据权利要求1-8中任一项所述的化合物或其立体异构体或药学上可接受的盐在制备用于治疗哺乳动物的雌激素受体依赖性或由雌激素受体介导的疾病的药物中的用途。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023557230A JP2024511044A (ja) | 2021-03-15 | 2022-03-14 | エストロゲン受容体モジュレーター |
EP22770451.7A EP4310079A1 (en) | 2021-03-15 | 2022-03-14 | Estrogen receptor antagonist |
KR1020237035079A KR20230157439A (ko) | 2021-03-15 | 2022-03-14 | 에스트로겐 수용체 조절제 |
AU2022240650A AU2022240650A1 (en) | 2021-03-15 | 2022-03-14 | Estrogen receptor antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110277849 | 2021-03-15 | ||
CN202110277849.3 | 2021-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022194096A1 true WO2022194096A1 (zh) | 2022-09-22 |
Family
ID=83246765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/080680 WO2022194096A1 (zh) | 2021-03-15 | 2022-03-14 | 雌激素受体调节剂 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4310079A1 (zh) |
JP (1) | JP2024511044A (zh) |
KR (1) | KR20230157439A (zh) |
CN (1) | CN115073493A (zh) |
AU (1) | AU2022240650A1 (zh) |
WO (1) | WO2022194096A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016202161A1 (zh) * | 2015-06-16 | 2016-12-22 | 江苏恒瑞医药股份有限公司 | 哌啶类衍生物、其制备方法及其在医药上的应用 |
US20170305909A1 (en) * | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Chemical compounds |
CN109219604A (zh) * | 2016-04-08 | 2019-01-15 | 豪夫迈·罗氏有限公司 | 四氢异喹啉雌激素受体调节剂及其用途 |
WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
WO2019223715A1 (zh) * | 2018-05-23 | 2019-11-28 | 江苏恒瑞医药股份有限公司 | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 |
-
2022
- 2022-03-14 KR KR1020237035079A patent/KR20230157439A/ko unknown
- 2022-03-14 WO PCT/CN2022/080680 patent/WO2022194096A1/zh active Application Filing
- 2022-03-14 JP JP2023557230A patent/JP2024511044A/ja active Pending
- 2022-03-14 EP EP22770451.7A patent/EP4310079A1/en active Pending
- 2022-03-14 AU AU2022240650A patent/AU2022240650A1/en active Pending
- 2022-03-14 CN CN202210249231.0A patent/CN115073493A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016202161A1 (zh) * | 2015-06-16 | 2016-12-22 | 江苏恒瑞医药股份有限公司 | 哌啶类衍生物、其制备方法及其在医药上的应用 |
CN109219604A (zh) * | 2016-04-08 | 2019-01-15 | 豪夫迈·罗氏有限公司 | 四氢异喹啉雌激素受体调节剂及其用途 |
US20170305909A1 (en) * | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Chemical compounds |
WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
WO2019192533A1 (zh) * | 2018-04-04 | 2019-10-10 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
WO2019223715A1 (zh) * | 2018-05-23 | 2019-11-28 | 江苏恒瑞医药股份有限公司 | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20230157439A (ko) | 2023-11-16 |
CN115073493A (zh) | 2022-09-20 |
EP4310079A1 (en) | 2024-01-24 |
JP2024511044A (ja) | 2024-03-12 |
AU2022240650A1 (en) | 2023-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102614939B1 (ko) | 피리미딘-융합고리 화합물 및 그의 제조방법과 용도 | |
CN110156786B (zh) | 嘧啶并环化合物及其制备方法和应用 | |
CN114085212B (zh) | 异吲哚啉类化合物、其制备方法、药物组合物及用途 | |
CN113454083A (zh) | Kras突变蛋白抑制剂 | |
ES2902050T3 (es) | Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1 | |
JP2022533398A (ja) | Kras g12cインヒビター及びその使用 | |
CN113286794A (zh) | Kras突变蛋白抑制剂 | |
CN110078741B (zh) | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 | |
US20230212170A1 (en) | Inhibitors of kras g12c protein and uses thereof | |
CN106749233B (zh) | 一类磺酰胺衍生物及其应用 | |
CN112778276A (zh) | 作为shp2抑制剂的化合物及其应用 | |
CA2993096A1 (en) | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | |
CN111065639A (zh) | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 | |
JP2020519564A (ja) | アミノピリミジン縮合5員複素環化合物、その中間体、製造方法、薬物組成物および使用 | |
TW202237597A (zh) | 新型egfr降解劑 | |
CN110655520A (zh) | 嘧啶并环化合物及其制备方法和应用 | |
CN114805311A (zh) | 螺环茚 | |
CN114805361B (zh) | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 | |
WO2022127827A1 (zh) | Kras g12c蛋白突变抑制剂、其制备方法、药物组合物及其应用 | |
CA3234693A1 (en) | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof | |
WO2022194096A1 (zh) | 雌激素受体调节剂 | |
EP4206197A1 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
CN102190669A (zh) | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 | |
WO2024006776A1 (en) | Estrogen receptor alpha degraders and medical use thereof | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22770451 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18282147 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023557230 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022240650 Country of ref document: AU Ref document number: 2022240650 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20237035079 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237035079 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022770451 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022240650 Country of ref document: AU Date of ref document: 20220314 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022770451 Country of ref document: EP Effective date: 20231016 |